SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • July 8th, 2024 • Xeris Biopharma Holdings, Inc. • Pharmaceutical preparations • Delaware
This Second Amended and Restated Employment Agreement (“Agreement”) is made as of July 7, 2024, by and among Xeris Biopharma Holdings, Inc., a Delaware corporation (the “Parent”), Xeris Pharmaceuticals, Inc., a Delaware corporation and wholly-owned subsidiary of the Parent (the “Company”), and John Shannon (the “Executive”) and is effective as of August 1, 2024 (the “Effective Date”)
Standard Contracts
July 7, 2024 Paul R. Edick Re: Transition Agreement Dear Paul:Transition Agreement • July 8th, 2024 • Xeris Biopharma Holdings, Inc. • Pharmaceutical preparations • Illinois
This letter confirms our agreement regarding your transition from the role of Chief Executive Officer of Xeris Biopharma Holdings Inc., a Delaware corporation (the “Parent”), and Xeris Pharmaceuticals, Inc., a Delaware corporation and wholly owned subsidiary of the Parent (the “Company”) and your future services as a Senior Advisor. The Board of Directors of the Parent (the “Board”) appreciates your substantial contributions to the Company, looks forward to your support as a Senior Advisor, and would like to make the transition to the Company’s new Chief Executive Officer (the “New CEO”) as seamless as possible.